Company intelligence / Profile preview
Numinus Wellness
- Ownership
- Private
- Employees
- ~150
- Development stage
- Commercial
Overview
Numinus Wellness operates a network of clinics in Canada and the US offering mental health services including psychiatry, therapy, ketamine-assisted therapy, transcranial magnetic stimulation (TMS), and psychedelic-assisted psychotherapy. The company also conducts clinical research on psychedelics such as psilocybin and MDMA for mental health conditions. It has been involved in Canada’s first compassionate access trial of MDMA for PTSD and a trial of psilocybin for substance use disorders. Its biosciences division holds licenses to test, sell, distribute—and eventually conduct research on—psychedelic substances.
- Therapeutic areas
- Psychiatry
- Modalities
- Small moleculePsychedelic compoundsDevice
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Numinus Wellness.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Numinus Wellness.